Clinical Trials

By Marta Catalfamo

Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients 

Principal Investigators: Brahm H Sega, MD. Roswell Park Cancer Institute. Buffalo, New York, United States, 14263 

Contact: Brahm H. Segal, MD, Phone: +1-716-845-5721 
ClinicalTrials.gov Identifier: NCT04379518 

Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 (COVID-19) Infection (PROTECT) 

Principal Investigators: Mark Sulkowski, MD. Johns Hopkins Hospital. Baltimore, Maryland, United States, 21287 

Contact: Mark Sulkowski, MD., Phone: +1 410-955-7538 

ClinicalTrials.gov Identifier: NCT04344600 

Early Treatment of Cytokine Storm Syndrome in Covid-19 

Principal Investigators: Walter W Chatham, MD. University of Alabama at Birmingham. Birmingham, Alabama, United States, 35294 

Contact: Angelia Kendrach, Phone: +1-205-996-5602 

ClinicalTrials.gov Identifier: NCT04362111 

InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic Patients With COVID-19 Infection ( ILIAD-7-US-O ) (ILIAD-7-US-O) 

Principal Investigators: Marcel van den Brink, MD, PhD and Stephen Pastores, MD. Memorial pSloan Kettering Cancer Center. New York, New York, United States, 10065 

Contact: Stephen Pastores, MD., Phone:+1 212-639-6673 

ClinicalTrials.gov Identifier: NCT04426201 

Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy 

Principal Investigators: Mayur S Narkhede, MD. University of Alabama at Birmingham. Birmingham, Alabama, United States, 35294 

Contact: Mayur Narkhede, Phone: +1-205-934-2248 

ClinicalTrials.gov Identifier: NCT04975555 

Safety and Efficacy of Interferon-Gamma 1b in Patients With Candidemia 

Principal Investigators: Dr. Frank vd Veerdonk. Radboud University. Nijmegen, Gelderland, Netherlands, 6525 GA 

Contact: Dr. Frank vd Veerdonk, Phone: 0031243618819 

ClinicalTrials.gov Identifier: NCT04979052 

Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral Therapy (ACTIVATE) 

Principal Investigators: Mathias Lichterfeld, MD, PhD. Massachusetts General Hospital CRS (MGH CRS). Boston, Massachusetts, United States, 02114 

Contact: Theresa Flynn, R.N., M.S.N., A.N.P, B.S.N, Phone: +1(617) 724-0072 

ClinicalTrials.gov Identifier: NCT02471430 

Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma 

Principal Investigators: Roxana S Dronca, MD. Mayo Clinic in Florida, Jacksonville, Florida, United States, 32224-9980 

Contact: Roxana S Dronca, MD, Phone: +1 855-776-0015 

ClinicalTrials.gov Identifier: NCT03865212 

Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity 

Principal Investigators: Robert Yarchoan, M.D. ational Cancer Institute. National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States, 20892 

Contact: Irene Ekwede, R.N., Phone: +1(240) 760-6126 

ClinicalTrials.gov Identifier: NCT00092222 

Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers 

Principal Investigators: Geraldine H O’Sullivan Coyne, M.D. National Cancer Institute. National Institutes of Health Clinical Center. Bethesda, Maryland, United States, 20892 

Contact: Ashley B Bruns, Phone: +1 (240) 858-3162 

ClinicalTrials.gov Identifier: NCT03388632 

Poor Response to Monoclonal Therapy in Asthma (PROCLAIM) 

Principal Investigators: Dominick Shaw, MBBS, FRCS, MD., Nottingham Respiratory BRU. Nottingham, United Kingdom, NG51PB. 

Contact: Yik L Pang, BMedSci, MBBS, MRCP, Phone: 01158231702 

ClinicalTrials.gov Identifier: NCT04114396 

Low-dose Interleukin-2 for the Reduction of Vascular Inflammation in Acute Coronary Syndromes – IVORY (IVORY) 

Principal Investigators: Joseph Cheriyan, MBChB,FRCP. Hospitals NHS Foundation Trust. Unversity of Cambridge. Cambridge, Cambridgeshire, United Kingdom, CB20QQ 

Contact: Heike Templin., Phone: +44(0)1223 250874 

ClinicalTrials.gov Identifier: NCT04241601 

TNFalpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 During TIL Treatment of Advanced Melanoma (TUNINTIL) 

Principal Investigators: Inge Marie Svane, MD. National Center for Cancer Immune Therapy Herlev Hospital, Copenhagen University. Copenhagen, Denmark. 

Brigitte Dréno, MD. CHU Nantes. Nantes, France 

Contact: Herlev Hospital, Phone: +45 38 68 38 68 

ClinicalTrials.gov Identifier: NCT04217473 

Treatment and Natural History Study of Lymphomatoid Granulomatosis 

Principal Investigators: Christopher J Melani, M.D. National Cancer Institute. National Institutes of Health Clinical Center, 9000 Rockville Pike. Bethesda, Maryland, United States, 20892 

Contact: NCI Medical Oncology Referral Office, Phone: (240) 760- 6050 

ClinicalTrials.gov Identifier: NCT00001379

Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas – INSTAL-101

Principal Investigators: Beth Israel Deaconess Medical Center. Boston, Massachusetts, United States, 02215

Contact: Eisai Medical Information, Phone: 1-888-274-2378

ClinicalTrials.gov Identifier: NCT04144140

Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma

Principal Investigators: Humphrey Gardner, Chief Medical Officer, MD, FCAP. Silicon Therapeutics. Boston, MA. United States, 02210

Contact: Salah Nabhan, MS   Phone: 479)530-3530

ClinicalTrials.gov Identifier: NCT04609579

Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer

Principal Investigators: Sunyoung Lee, MD. M.D. Anderson Cancer Center. Houston, Texas, United States, 77030

Contact:  Sunyoung Lee,  Phone: 713-792-2828

ClinicalTrials.gov Identifier: NCT04380545

Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Mel66)

Principal Investigators: Craig L Slingluff, Jr, Professor of Surgery; Director, Human Immune Therapy Center, University of Virginia. Charlottesville, Virginia, United States, 22908.

Contact:  Adela Mahmutovic, BS  Phone: 14349826714

ClinicalTrials.gov Identifier: NCT04364230

Clinical Study for the Treatment With Interferon-ß-1a (IFNß-1a) of COVID-19 Patients (INTERCOP)

Principal Investigators: Emanuele Bosi, Professor. IRCCS Ospedale San Raffaele. Milano, Italy, 20132

Contact:  Patrizia Rovere Querini, Professor  Phone: 00390226426768 

ClinicalTrials.gov Identifier: NCT04449380

Rintatolimod and IFN Alpha-2b for the Treatment of Mild or Moderate COVID-19 Infection in Cancer Patients

Principal Investigators: Brahm H. Segal, MD. Roswell Park Cancer Institute. Buffalo, New York, United States, 14263  

Contact:  Pawel Kalinski, MD, Phone: 716-845-5721

ClinicalTrials.gov Identifier: NCT04379518

Study of SRF388 in Patients With Advanced Solid Tumors

Principal Investigators: Daniel Morgensztern, MD, Washington University School of Medicine – St. Louis. Saint Louis, Missouri, United States, 63110

Contact:  Jessica Archambault,  Phone: 314-362-8246

ClinicalTrials.gov Identifier: NCT04374877

Peg-Interferon Alpha 2b Combined With Two Intravenous Broadly HIV-1 Neutralizing Antibodies 3BNC117 and 10-1074 (BEAT-2) (BEAT-2)

Principal Investigators: Luis J Montaner, DVM, DPhil. The Wistar Institute. University of Pennsylvania. Philadelphia, Pennsylvania, United States, 19104

Contact:   Pablo Tebas, M.D, Phone: 215-662-8217   

ClinicalTrials.gov Identifier: NCT03588715

Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia

Principal Investigators: Milos Miljkovic, M.D. National Cancer Institute. National Institutes of Health Clinical Center. Bethesda, Maryland, United States, 20892

Contact:   NCI Medical Oncology Referral Office, Phone: (240) 760-6050

ClinicalTrials.gov Identifier: NCT03759184

Use of the Interleukin-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection

Principal Investigators: Nada Alachkar, MD. Johns Hopkins Hospital. Baltimore, Maryland, United States, 21287

Contact:  Study Manager Phone: 4105508858

ClinicalTrials.gov Identifier: NCT04363502

Rintatolimod and IFN Alpha-2b for the Treatment of Mild or Moderate COVID-19 Infection in Cancer Patients’

Principal Investigators: Brahm H Segal, MD. Roswell Park Cancer Institute. Buffalo, New York, United States, 14263

Contact:  Pawel Kalinski , MD Phone: 716-845-5721

ClinicalTrials.gov Identifier: NCT04379518

Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in COVID-19 (ILIAD)

Principal Investigators: Jordan Feld, MD. Toronto General Hospital. Toronto, Ontario, Canada, M5G 2C4

Contact:  Seham Noureldin, PhD, Phone: 416-340-4800 ext 8681

ClinicalTrials.gov Identifier: NCT04354259

Recombinant Interleukin-7 (CYT107) to Treat Patients With Refractory Nontuberculous Mycobacterial Lung Disease (IMPULSE-7)

Principal Investigators: Andrej SPEC, MD. Washington University. Saint Louis, Missouri, United States, 63110

Contact:  Andrej SPEC, MD, Phone: 314-747-1725

ClinicalTrials.gov Identifier: NCT04154826